Yıl: 2021 Cilt: 14 Sayı: 3 Sayfa Aralığı: 598 - 603 Metin Dili: İngilizce DOI: 10.31362/patd.809407 İndeks Tarihi: 16-06-2022

Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?

Öz:
Purpose: Neutrophile-Lymphocyte (NLR) and Platelet-Lymphocyte ratio (PLR) comparison is an easy to use and cost-effective method in diagnosis of some cancers and diseases. In this study, we aimed to investigate if NLR/PLR ratio evaluation could be utilized in diagnosis of testicular malignencies especially in early-term with occult metastasis. Materials and methods: A total of 40 patients at stage-I, who have undergone radical inguinal orchiectomy intervention for testicular tumor between 2015 and 2019, and 43 control individuals without any testicular complaints were included in this retrospective study. The relationship between pathological risk factors for occult metastatic disease in Stage-I testicular cancer and NLR/PLR values were investigated. Results: The average age was 30.05 years, and there was no significant difference between the groups by means of age (p=0.150). The NLR and PLR values of the tumor group were prominently higher in the patient group, when compared with the control group (p=0.001 and p=0.016, respectively). In the correlation analysis between risk-factors for occult metastatic disease in Stage-I testicular cancer and NLR/PLR, we have found that only a significant correlation was present in terms of tumor size. Conclusion: As a result, we have concluded that NLR increases in all types of testicular tumors. We suggest that higher NLR ratio values can be used as prognostic marker in clinical practice.
Anahtar Kelime:

Nötrofil lenfosit oranı evre 1 testis tümöründe okkült metastaz parametrelerinde belirteç olabilir mi?

Öz:
Amaç: Nötrofil-Lenfosit ve Trombosit-Lenfosit oranı (NLR/PLR) karşılaştırması, bazı kanserlerin ve hastalıkların tanısında kullanımı kolay ve düşük maliyetli bir yöntemdir. Bu çalışmada, özellikle okkült metastazlı erken dönem testis malignitelerinin tanısında NLR/PLR oranı değerlendirmesinin kullanılıp kullanılamayacağını araştırmayı amaçladık. Gereç ve yöntem: 2015-2019 yılları arasında testis tümörü için radikal inguinal orşiektomi müdahalesi yapılan hastalar retrospektif olarak incelendi. Çalışmaya testis tümör evre-I olan 40 hasta ve herhangi bir testis şikayeti olmayan 43 hasta kontrol grubu olarak çalışmaya dahil edildi. Evre-I testis kanserinde okkült metastatik hastalık için patolojik risk faktörleri ile NLR/PLR değerleri arasındaki ilişki araştırıldı. Bulgular: Hastaların yaş ortalaması 30,05 yıl idi ve gruplar arasında yaş bakımından anlamlı fark yoktu (p=0,150). Tümör grubunun NLR ve PLR oranı değerleri testis tümörlü hastalarda kontrol grubuna göre belirgin olarak yüksekti (sırasıyla p=0,001 ve p=0,016). Evre-I testis kanseri ve NLR/PLR'de okkült metastatik hastalık için risk faktörleri arasındaki korelasyon analizinde sadece tümör boyutu açısından anlamlı bir korelasyon olduğunu bulduk. Sonuç: Sonuç olarak, tüm testis tümörlerinde NLR'nin arttığı sonucuna vardık. Klinik uygulamada prognostik belirteç olarak daha yüksek NLR oranı değerlerinin kullanılabileceğini önermekteyiz.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Znaor A, Lortet Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014;65:1095-1106. https://doi. org/10.1016/j.eururo.2013.11.004
  • 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225- 249. https://doi.org/10.3322/caac.20006
  • 3. Şahin A, Toprak T, Kutluhan MA, Vural Y, Ürkmez A, Verit A. Increased neutrophil/lymphocyte ratio in testicular cancer. Arch Ital Urol Androl 2019;91:97-101. https://doi.org/10.4081/aiua.2019.2.97
  • 4. Borghesi M, Brunocilla E, Schiavina R, et al. Role of testis sparing surgery in the conservative management of small testicular masses: oncological and functional perspectives. Actas Urol Esp 2015;39:57-62. https:// doi.org/10.1016/j.acuro.2014.02.020
  • 5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature 2008;454:436-444. https://doi.org/10.1038/nature07205
  • 6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899. https://doi.org/10.1016/j.cell.2010.01.025
  • 7. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221- 233. https://doi.org/10.1158/1541-7786.MCR-05-0261
  • 8. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283-287. https://doi.org/10.1023/ B:AGEN.0000029415.62384.ba
  • 9. Lee JS, Kim NY, Na SH, Youn YH, Shin CS. Reference values of neutrophil-lymphocyte ratio, lymphocytemonocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Medicine (Baltimore) 2018;97:e11138. https://doi. org/10.1097/MD.0000000000011138
  • 10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. https://doi. org/10.1016/S0140-6736(00)04046-0
  • 11. Vassilatou E, Fisfis M, Morphopoulos G, et al. Papillary thyroid carcinoma producing granulocyte-macrophage colony-stimulating factor is associated with neutrophilia and eosinophilia. Hormones (Athens) 2006;5:303-309. https://doi.org/10.14310/horm.2002.11196
  • 12. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1”versus “N2” TAN. Cancer Cell 2009;16:183-194. https://doi.org/10.1016/j.ccr.2009.06.017
  • 13. Yuksel OH, Verit A, Sahin A, Urkmez A, Uruc F. White blood cell counts and neutrophil to lymphocyte ratio in the diagnosis of testicular cancer: a simple secondary serum tumor marker. Int Braz J Urol 2016;42:53-59. https://doi.org/10.1590/S1677-5538.IBJU.2014.0593
  • 14. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008;102:653-657. https://doi.org/10.1016/j. amjcard.2008.05.006
  • 15. Schaider H, Oka M, Bogenrieder T, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL 8. Int J Cancer 2003;103:335- 343. https://doi.org/10.1002/ijc.10775
  • 16. Gokcen K, Dundar G, Gulbahar H, Gokce G, Gultekin EY. Can routine peripheral blood counts like neutrophil to lymphocyte ratio be beneficial in prediagnosis of testicular cancer and its stages? J Res Med Sci 2018;23:64. https://doi.org/10.4103/jrms. JRMS_1009_16
  • 17. Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013;107:493-497. https://doi. org/10.1002/jso.23270
  • 18. Bolat D, Aydoğdu Ö, Polat S, et al. Predictive value of preoperative neutrophil-to-lymphocyte ratio on the prognosis of germ cell testicular tumors. Turk J Urol 2017;43:55-61. https://doi.org/10.5152/tud.2016.38924
  • 19. Ilktac A, Dogan B, Ersoz C, Akcay M, Akbulut H. The relationship of neutrophil to lymphocyte ratio with testicular cancer. Int Braz J Urol 2020;46:101-107. https://doi.org/10.1590/S1677-5538.IBJU.2019.0321
APA baser a, ARAS B (2021). Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. , 598 - 603. 10.31362/patd.809407
Chicago baser aykut,ARAS Bekir Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. (2021): 598 - 603. 10.31362/patd.809407
MLA baser aykut,ARAS Bekir Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. , 2021, ss.598 - 603. 10.31362/patd.809407
AMA baser a,ARAS B Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. . 2021; 598 - 603. 10.31362/patd.809407
Vancouver baser a,ARAS B Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. . 2021; 598 - 603. 10.31362/patd.809407
IEEE baser a,ARAS B "Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?." , ss.598 - 603, 2021. 10.31362/patd.809407
ISNAD baser, aykut - ARAS, Bekir. "Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?". (2021), 598-603. https://doi.org/10.31362/patd.809407
APA baser a, ARAS B (2021). Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. Pamukkale Tıp Dergisi, 14(3), 598 - 603. 10.31362/patd.809407
Chicago baser aykut,ARAS Bekir Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. Pamukkale Tıp Dergisi 14, no.3 (2021): 598 - 603. 10.31362/patd.809407
MLA baser aykut,ARAS Bekir Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. Pamukkale Tıp Dergisi, vol.14, no.3, 2021, ss.598 - 603. 10.31362/patd.809407
AMA baser a,ARAS B Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. Pamukkale Tıp Dergisi. 2021; 14(3): 598 - 603. 10.31362/patd.809407
Vancouver baser a,ARAS B Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?. Pamukkale Tıp Dergisi. 2021; 14(3): 598 - 603. 10.31362/patd.809407
IEEE baser a,ARAS B "Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?." Pamukkale Tıp Dergisi, 14, ss.598 - 603, 2021. 10.31362/patd.809407
ISNAD baser, aykut - ARAS, Bekir. "Can neutrophil lymphocyte ratio be a marker in stage 1 testicular tumor occult metastasis parameters?". Pamukkale Tıp Dergisi 14/3 (2021), 598-603. https://doi.org/10.31362/patd.809407